19 studies found for:    EC-145
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EC145;   Drug: EC145 + Docetaxel;   Drug: Docetaxel;   Drug: EC20
2 Completed Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)
Condition: Cancer
Interventions: Drug: Vintafolide IV Bolus;   Drug: Vintafolide IV Infusion
3 Completed Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)
Condition: Ovarian Cancer
Interventions: Drug: Vintafolide;   Drug: pegylated liposomal doxorubicin (PLD);   Other: EC20
4 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)
Conditions: Ovarian Cancer;   Endometrial Cancer
Interventions: Drug: Vintafolide;   Drug: Ertafolide
5 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Condition: Adenocarcinoma of the Lung
Interventions: Drug: Vintafolide;   Drug: Etarfolatide
6 Active, not recruiting A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Condition: Advanced Cancer
Interventions: Drug: Vintafolide;   Drug: Carboplatin;   Drug: Paclitaxel
7 Enrolling by invitation Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Condition: Solid Tumors
Intervention: Drug: EC145
8 Suspended Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Condition: Ovarian Cancer
Interventions: Drug: EC145;   Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);   Drug: placebo;   Drug: EC20
9 Terminated A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
Condition: Solid Tumor
Intervention: Drug: Vintafolide
10 Withdrawn Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Condition: Breast Neoplasms
Interventions: Drug: Vintafolide 2.5 mg;   Drug: Paclitaxel 80 mg/m^2;   Drug: Etarfolatide;   Drug: Folic acid;   Drug: Premedication for Paclitaxel
11 Completed LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Condition: Hyperlipidemia
Interventions: Biological: evolocumab (AMG 145);   Other: Ezetimibe;   Other: Placebo (administered subcutaneously);   Other: Placebo (administered orally);   Drug: Atorvastatin;   Drug: Rosuvastatin;   Drug: Simvastatin
12 Recruiting Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
13 Completed Fractional CO2 Treatment of Acne Scars in Asians
Condition: Acne Scar, Wrinkle
Intervention: Device: Fractional CO2 Laser
14 Active, not recruiting The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Conditions: Locally Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: NKTR-102;   Drug: Treatment of Physician's Choice (TPC)
15 Completed A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment
Conditions: Postherpetic Neuralgia (PHN);   Peripheral Nerve Injury (PNI);   Non-diabetic Painful Peripheral Polyneuropathy
Interventions: Drug: Qutenza;   Drug: Pregabalin
16 Active, not recruiting
Has Results
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Condition: Metastases, Brain
Interventions: Drug: capecitabine;   Drug: lapatinib;   Drug: trastuzumab
17 Recruiting Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: BAF312;   Drug: Placebo
18 Completed
Has Results
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
Conditions: Thrombosis, Venous;   Superficial Thrombophlebitis
Intervention: Drug: Fondaparinux 2.5mg or placebo
19 Recruiting Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
Condition: Prostate Cancer
Interventions: Drug: GDC-0068;   Drug: GDC-0980;   Drug: placebo;   Drug: abiraterone;   Drug: prednisone

Indicates status has not been verified in more than two years